The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)

中国抗癌协会妇科肿瘤专业委员会; 中华医学会病理学分会; 国家病理质控中心

doi:10.19401/j.cnki.1007-3639.2021.11.012

您当前的位置：

首页 >

文章列表页 >

The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)

更新时间：2025-12-31

- The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)
- China Oncology Vol. 31, Issue 11, Pages: 1126-1144(2021)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.11.012
  CLC：
- Published Online：03 December 2021，
  
  Published：03 December 2021
- 稿件说明：
移动端阅览
中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. 子宫内膜癌分子检测中国专家共识（2021年版）[J]. 中国癌症杂志, 2021, 31(11): 1126-1144.

中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)[J]. China Oncology, 2021, 31(11): 1126-1144.
中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. 子宫内膜癌分子检测中国专家共识（2021年版）[J]. 中国癌症杂志, 2021, 31(11): 1126-1144. DOI： 10.19401/j.cnki.1007-3639.2021.11.012.

中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)[J]. China Oncology, 2021, 31(11): 1126-1144. DOI： 10.19401/j.cnki.1007-3639.2021.11.012.

摘要

近年来，高通量测序技术的发展加深了我们对子宫内膜癌发病机制和分子遗传特征的理解，基于分子遗传特征的个体化精准治疗，革新了子宫内膜癌的治疗模式。但国内对子宫内膜癌的遗传风险筛查流程、分子分型检测策略及其对患者预后评估和治疗选择的临床价值、晚期子宫内膜癌患者分子检测的选择及临床价值探讨和认识尚有不足。根据子宫内膜癌分子病理学检测与精准治疗领域的最新研究进展，中国抗癌协会妇科肿瘤专业委员会、中华医学会病理学分会及国家病理质控中心针对子宫内膜癌组织标本的分子病理学检测制订了《子宫内膜癌分子检测中国专家共识》（以下简称本共识），希望通过本共识，提高中国临床工作者对于子宫内膜癌分子检测的认识，以指导与规范子宫内膜癌分子检测在国内的临床应用。

Abstract

Recently

our understanding of the pathogenesis and molecular genetic characteristics of endometrial cancer has been improved along with the development of high-throughput sequencing technology. Precision medicine based on genetic characteristics has already transformed the care of endometrial cancer. However

there is no specific consensus in China on the methods and strategies of genetic screening for hereditary syndrome

molecular classification and other biomarkers testing in endometrial cancer. Based on the most recent advances in molecular classification and precision medicine in endometrial cancer

The Society of Gynecological Cancer of China Anti-Cancer Association

Chinese Society of Pathology of the Chinese Medical Association and National Pathology Quality Control Center have formulated “The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer”

in order to improve the understanding of molecular testing among gynecologic oncologists

pathologists

and other specialists

and further standardize the application of molecular testing in endometrial cancer in China.

关键词

Keywords

references

Views

4643

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research status and progress of third-line treatment for metastatic colorectal cancer

Discovery and preliminary validation of five early gastric cancer biomarkers, including TAGLN2 and CTSD, based on serum proteomics

Significant fundamental translational research on breast cancer in China: progress and prospects

The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer

Progress in treatment of gynecological cancer in 2023

Related Author

Xianbao ZHAN

Xiaobo PENG

Yue WU

Tong YIN

Jingyu LIU

Wenfei HU

Kewei DU

Shangdi ZHANG

Related Institution

Department of Oncology, The First Affiliated Hospital of Naval Medical University

Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University

Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University

Department of General Surgery, People's Hospital of Zhenhai

AI问答

⁰